Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

37.40B

Market cap37.40B

Price-Earnings ratio

106.57

Price-Earnings ratio106.57

Dividend yield

—

Dividend yield—

Average volume

1.37M

Average volume1.37M

High today

$255.35

High today$255.35

Low today

$246.49

Low today$246.49

Open price

$253.54

Open price$253.54

Volume

642.21K

Volume642.21K

52 Week high

$258.78

52 Week high$258.78

52 Week low

$148.51

52 Week low$148.51

Stock Snapshot

With a market cap of 37.4B, Biogen(BIIB) trades at $252.99. The stock has a price-to-earnings ratio of 106.57.

As of 2026-11-04, Biogen(BIIB) stock has fluctuated between $246.49 and $255.35. The current price stands at $252.99, placing the stock +2.6% above today's low and -0.9% off the high.

The Biogen(BIIB)'s current trading volume is 642.21K, compared to an average daily volume of 1.37M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $258.78 and a 52-week low of $148.51.

BIIB News

MarketWatch 2d

Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch

...

Simply Wall St 4d

Biogen Just Gave Investors Something To Think About

Biogen (BIIB) is back in focus after fresh Alzheimer’s data and mixed third quarter figures, as investors weigh revenue growth, continued Leqembi uptake, and th...

Benzinga 6d

These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

Biogen Inc (NASDAQ:BIIB) on Wednesday posted better-than-expected earnings for the third quarter. The company posted adjusted earnings of $2.62 per share, beat...

Analyst ratings

70%

of 37 ratings

Buy

70.3%

Hold

27%

Sell

2.7%

More BIIB News

TipRanks 7d

Biogen Q3 Earnings Call Signals Growth-Led Comeback

Biogen Inc. ((BIIB)) has held its Q3 earnings call. Read on for the main highlights of the call. Biogen’s latest earnings call struck a decidedly upbeat tone,...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.